IL250484B - Heterovesicular compounds and their use in the treatment of tuberculosis - Google Patents
Heterovesicular compounds and their use in the treatment of tuberculosisInfo
- Publication number
- IL250484B IL250484B IL250484A IL25048417A IL250484B IL 250484 B IL250484 B IL 250484B IL 250484 A IL250484 A IL 250484A IL 25048417 A IL25048417 A IL 25048417A IL 250484 B IL250484 B IL 250484B
- Authority
- IL
- Israel
- Prior art keywords
- cpmpounds
- heterobicyclic
- tuberculosis
- treatment
- heterobicyclic cpmpounds
- Prior art date
Links
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014174528 | 2014-08-28 | ||
| PCT/JP2015/004371 WO2016031255A1 (en) | 2014-08-28 | 2015-08-28 | Heterobicyclic compounds and their use for the treatment of tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL250484A0 IL250484A0 (en) | 2017-03-30 |
| IL250484B true IL250484B (en) | 2020-04-30 |
Family
ID=54105947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL250484A IL250484B (en) | 2014-08-28 | 2017-02-07 | Heterovesicular compounds and their use in the treatment of tuberculosis |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10053446B2 (enExample) |
| EP (1) | EP3186240B9 (enExample) |
| JP (1) | JP6625612B2 (enExample) |
| KR (1) | KR102418413B1 (enExample) |
| CN (1) | CN106795117B (enExample) |
| AP (1) | AP2017009788A0 (enExample) |
| AR (1) | AR101704A1 (enExample) |
| AU (1) | AU2015307873B2 (enExample) |
| BR (1) | BR112017003231B1 (enExample) |
| CA (1) | CA2959478C (enExample) |
| CY (1) | CY1122286T1 (enExample) |
| DK (1) | DK3186240T3 (enExample) |
| EA (1) | EA038414B1 (enExample) |
| ES (1) | ES2743788T3 (enExample) |
| HR (1) | HRP20191486T2 (enExample) |
| HU (1) | HUE045025T2 (enExample) |
| IL (1) | IL250484B (enExample) |
| LT (1) | LT3186240T (enExample) |
| MX (1) | MX2017002312A (enExample) |
| MY (1) | MY189098A (enExample) |
| NZ (1) | NZ729064A (enExample) |
| PH (1) | PH12017500290B1 (enExample) |
| PL (1) | PL3186240T3 (enExample) |
| PT (1) | PT3186240T (enExample) |
| SG (1) | SG11201700882XA (enExample) |
| SI (1) | SI3186240T1 (enExample) |
| TW (1) | TWI687409B (enExample) |
| WO (1) | WO2016031255A1 (enExample) |
| ZA (1) | ZA201700916B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101704A1 (es) * | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
| JP6905506B2 (ja) * | 2016-02-26 | 2021-07-21 | 大塚製薬株式会社 | ピペリジン誘導体 |
| KR20210021042A (ko) | 2018-06-15 | 2021-02-24 | 카딜라 핼쓰캐어 리미티드 | 포유동물 감염 치료를 위한 신규한 화합물 |
| JP2023085582A (ja) * | 2020-05-11 | 2023-06-21 | 大塚製薬株式会社 | ジヒドロキノリノン化合物の共結晶 |
| WO2022039506A1 (ko) * | 2020-08-19 | 2022-02-24 | 주식회사 미토이뮨테라퓨틱스 | Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제 |
| CN116102537B (zh) * | 2021-11-10 | 2024-10-01 | 四川大学 | 一种喹啉酮类衍生物及其制备方法和用途 |
| CN116589448B (zh) * | 2023-04-24 | 2025-10-28 | 西南交通大学 | 一种3,4-二氢喹啉酮衍生物及其应用 |
| WO2025183017A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
| WO2025183016A1 (ja) * | 2024-02-26 | 2025-09-04 | 大塚製薬株式会社 | Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
| TWI347946B (en) | 2002-10-11 | 2011-09-01 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
| GB0319150D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| AU2004285811B2 (en) * | 2003-10-31 | 2008-06-12 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis |
| JP4761756B2 (ja) * | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| ZA200602184B (en) * | 2003-10-31 | 2007-10-31 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis |
| PL2489659T3 (pl) * | 2004-06-24 | 2018-06-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą atp |
| EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| WO2010045987A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials |
| RU2540860C2 (ru) | 2009-07-31 | 2015-02-10 | Глоубал Элаенс Фор Тб Драг Дивелопмент | Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение |
| JP5916739B2 (ja) | 2011-04-15 | 2016-05-11 | 大塚製薬株式会社 | ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物 |
| AR101704A1 (es) * | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
| JP6905506B2 (ja) * | 2016-02-26 | 2021-07-21 | 大塚製薬株式会社 | ピペリジン誘導体 |
-
2015
- 2015-08-27 AR ARP150102746A patent/AR101704A1/es active IP Right Grant
- 2015-08-27 TW TW104128109A patent/TWI687409B/zh active
- 2015-08-28 WO PCT/JP2015/004371 patent/WO2016031255A1/en not_active Ceased
- 2015-08-28 EA EA201790464A patent/EA038414B1/ru unknown
- 2015-08-28 CA CA2959478A patent/CA2959478C/en active Active
- 2015-08-28 US US15/506,887 patent/US10053446B2/en active Active
- 2015-08-28 HU HUE15763096A patent/HUE045025T2/hu unknown
- 2015-08-28 PT PT15763096T patent/PT3186240T/pt unknown
- 2015-08-28 SG SG11201700882XA patent/SG11201700882XA/en unknown
- 2015-08-28 MX MX2017002312A patent/MX2017002312A/es active IP Right Grant
- 2015-08-28 KR KR1020177007855A patent/KR102418413B1/ko active Active
- 2015-08-28 MY MYPI2017700649A patent/MY189098A/en unknown
- 2015-08-28 EP EP15763096.3A patent/EP3186240B9/en active Active
- 2015-08-28 NZ NZ729064A patent/NZ729064A/en unknown
- 2015-08-28 PH PH1/2017/500290A patent/PH12017500290B1/en unknown
- 2015-08-28 ES ES15763096T patent/ES2743788T3/es active Active
- 2015-08-28 DK DK15763096.3T patent/DK3186240T3/da active
- 2015-08-28 CN CN201580045974.4A patent/CN106795117B/zh active Active
- 2015-08-28 AU AU2015307873A patent/AU2015307873B2/en active Active
- 2015-08-28 BR BR112017003231-7A patent/BR112017003231B1/pt active IP Right Grant
- 2015-08-28 JP JP2017507903A patent/JP6625612B2/ja active Active
- 2015-08-28 HR HRP20191486TT patent/HRP20191486T2/hr unknown
- 2015-08-28 LT LTEP15763096.3T patent/LT3186240T/lt unknown
- 2015-08-28 AP AP2017009788A patent/AP2017009788A0/en unknown
- 2015-08-28 PL PL15763096T patent/PL3186240T3/pl unknown
- 2015-08-28 SI SI201530868T patent/SI3186240T1/sl unknown
-
2017
- 2017-02-06 ZA ZA2017/00916A patent/ZA201700916B/en unknown
- 2017-02-07 IL IL250484A patent/IL250484B/en active IP Right Grant
-
2018
- 2018-07-09 US US16/029,850 patent/US10464926B2/en active Active
-
2019
- 2019-08-26 CY CY20191100906T patent/CY1122286T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| PL3218005T3 (pl) | Związki oddziałujące z glikanami i sposoby ich zastosowania | |
| PL3089971T3 (pl) | Związki i sposoby ich zastosowania | |
| IL250484B (en) | Heterovesicular compounds and their use in the treatment of tuberculosis | |
| IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
| IL251904A0 (en) | Epilimod for use in the treatment of melanoma | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| ZA201606450B (en) | Compounds and their methods of use | |
| PL3129398T3 (pl) | Nowe środki medyczne i ich zastosowanie | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| GB201418541D0 (en) | Materials for use with general hyperthermia treatment | |
| GB201403697D0 (en) | Compounds and methods of use | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use | |
| AU2014901480A0 (en) | Agents and methods of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |